Introduction
The GISSI study in 1986 1 convincingly showed that the mortality in acute myocardial infarction was significantly reduced by early treatment with intravenous streptokinase. This reduction in mortality was confirmed by IS1S-2 (second international study of infarct survival using streptokinase)2, by AIMS (APSAC intervention mortality study using anisoylated plasminogen streptokinase activated complexj", and by ASSET (Anglo-Scandinavian study of early thrombolysis using tissue plasminogen activator)', There is now general agreement that thrombolysis within 24 h is beneficial and that treatment within 6 h of the onset of pain will result in an approximate 25% reduction in mortality.
We decided to perform a retrospective analysis to determine the proportion of patients with myocardial infarction admitted to our unit who received thrombolytic therapy together with the number of those who failed to receive such treatment because of uncertainty in diagnosis at the time of admission. The results led us to develop an emergency cardiac enzyme estimation service for this group of patients and a further analysis was performed after a run-in period to determine whether this increased uptake of thrombolytic therapy.
Patients and methods

Retrospectioe analysis
Data was collected on all patients with proven myocardial infarction admitted under the care of one consultant physician (CES) over a period of 6 months. Forty-seven patients (42 men, 5 women, age range 33-79 years, mean 58 years) were studied.
As a routine procedure all patients had a blood sample taken immediately on admission for storage and estimation of serum creatinine kinase (ooK) and aspartate transaminase on the next working day. Myocardial infarction was considered proven if, over a 3-day period, serial ECGs revealed typical evolutionary changes of infarction and/or cardiac enzymes were elevated to twice the normal level. The proportion of patients with definite myocardial infarction receiving thrombolytic therapy was determined. The number not receiving this treatment was also noted and divided into two groups; those 
Prospective analysis
Two months after the emergency cardiac enzyme service was introduced a prospective analysis was performed on all patients with acute myocardial infarctions admitted to the coronary care unit over a 2-month period. Forty-seven patients (34 men and 13 women, age range 39-79 years, mean 61 years) were studied.
The proportion receiving thrombolytic therapy was again noted; those with a typical syndrome and those with an atypical syndrome but raised SCK. The number not being treated were also determined; those with contra-indications or who presented late and those with atypical syndrome and normal SCK.
Results
In the retrospective series 38 out of the 47 patients with proven myocardial infarction were eligible for thrombolysis but only 28 received treatment because of uncertainty in diagnosis in the remaining 10. Nine patients were ineligible because of specific contraindications or late presentation (24 h after onset of pain). In the prospective series following the introduction of urgent SCK, 34 out of the 47 patients were eligible for thrombolysis, and it was administered to 31 patients. Thirteen were ineligible because of contra-indications or late presentation.
The introduction of urgent SCK therefore increased the number of eligible patients treated from 73.7% (28/38) to 91.2% (31134) (P=0.05; Fisher's Exact Test).
In the retrospective series those who failed to receive treatment but who were later found to have raised cardiac enzymes numbered 6/38 (15.8%) and in the prospective series those who received treatment on the basis of a raised urgent SCK were 5/34 (14.7%). Combining both series about 15% of patients ultimately shown to have a myocardial infarction and to be eligible for thrombolysis present with an uncertain diagnosis. This uncertainty can be eliminated by an urgent SCK estimation.
No false positive results were obtained and no patient was treated inappropriately.
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Cost of emergency SCK service Reagent costs are £3.00 per sample (including control). During 2 months, 65 estimations were performed on those patients in whom the diagnosis of myocardial infarction was uncertain. Of these, 56 were performed out-of-hours which, on the basis of a £10.89 MLSO call out fee, could theoretically increase the cost to £396.00 per month. However, the majority of out-of-hours tests are performed in conjunction with other investigations and the MLSO call out fee is not necessarily applicable to this costing.
Discussion
The traditional role of cardiac enzyme estimation has been to retrospectively confirm the diagnosis of myocardial infarction. Previous studies have shown that cardiac enzymes have little or no value in excluding the diagnosis of myocardial infarction in the emergency room''". We have, however, looked at a new role for cardiac enzymes, that of usefulness and adding weight to the diagnosis of myocardial infarction. The fact that the ECG can remain normal for several hours after infarction can make the diagnosis difficult, particularly ifthe history of pain is uncertain or atypical. Serum creatinine kinase begins to rise 3 h after myocardial infarctions. This is within the scale where thrombolysis is still effective and the measurement of creatinine kinase in patients with suspected myocardial infarction but who have an uncertain history and no acute changes on the ECG can be very useful in helping the junior doctor to decide whether or not to administer thrombolytic therapy.
Our study not only confirms the usefulness of urgent creatinine kinase in a sub-group of patients with suspected myocardial infarction, but also the value of medical audit. Retrospective analysis revealed a deficiency which was not obvious, discussion with colleagues led to implementation of change and further evaluation confirmed an improvement in patient care, though at minimal cost.
